- Home
- CASK vs MYNZ Comparison
CASK vs MYNZ Comparison
Compare CASK & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASK
- MYNZ
- Stock Information
- Founded
- CASK 2011
- MYNZ 2021
- Country
- CASK United States
- MYNZ Germany
- Employees
- CASK N/A
- MYNZ N/A
- Industry
- CASK
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- CASK
- MYNZ Health Care
- Exchange
- CASK NYSE
- MYNZ Nasdaq
- Market Cap
- CASK 6.5M
- MYNZ 7.2M
- IPO Year
- CASK 2024
- MYNZ 2021
- Fundamental
- Price
- CASK $0.61
- MYNZ $3.20
- Analyst Decision
- CASK
- MYNZ Buy
- Analyst Count
- CASK 0
- MYNZ 2
- Target Price
- CASK N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- CASK 123.3K
- MYNZ 105.1K
- Earning Date
- CASK 05-25-2025
- MYNZ 05-06-2025
- Dividend Yield
- CASK N/A
- MYNZ N/A
- EPS Growth
- CASK N/A
- MYNZ N/A
- EPS
- CASK N/A
- MYNZ N/A
- Revenue
- CASK $7,522,832.00
- MYNZ $893,991.00
- Revenue This Year
- CASK N/A
- MYNZ $42.95
- Revenue Next Year
- CASK N/A
- MYNZ N/A
- P/E Ratio
- CASK $23.41
- MYNZ N/A
- Revenue Growth
- CASK N/A
- MYNZ N/A
- 52 Week Low
- CASK $0.40
- MYNZ $0.18
- 52 Week High
- CASK $4.00
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- CASK N/A
- MYNZ 40.90
- Support Level
- CASK N/A
- MYNZ $3.03
- Resistance Level
- CASK N/A
- MYNZ $3.31
- Average True Range (ATR)
- CASK 0.00
- MYNZ 0.35
- MACD
- CASK 0.00
- MYNZ 0.06
- Stochastic Oscillator
- CASK 0.00
- MYNZ 61.80
About CASK HERITAGE DISTILLING HOLDING COMPANY INC
Heritage Distilling Holding Co Inc is a craft distiller producing, marketing and selling a diverse line of award-winning craft spirits, including whiskeys, vodkas, gins, rums, and ready-to-drink canned cocktails. The company sells its products through wholesale distribution, directly to consumers through its owned and operated distilleries and tasting rooms located in Washington and Oregon and by shipping directly to consumers online where legal. Currently, It sells products primarily in the Pacific Northwest with limited distribution in other states throughout the U.S.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.